Study #2022-0685
Phase II investigation of Pembrolizumab in combination with Bevacizumab and Oral Cyclophosphamide in patients with high grade Ovarian Cancer and surgically documented minimal residual disease after frontline therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab, Bevacizumab, Cyclophosphamide
Description
To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer
Study phase:
Phase II
Physician name:
Amir Jazaeri
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.